创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

丙酸氟替卡松联合特布他林与异丙托溴铵雾化治疗儿童哮喘急性发作的效果

Effect of Fluticasone Propionate Combined with Terbutaline and Ipratropium Bromide Nebulized Inhalation for the Treatment of Acute Asthma Attacks in Children

  • 摘要: 目的 分析丙酸氟替卡松联合特布他林、异丙托溴铵雾化吸入疗法在儿童哮喘急性发作中的应用效果。方法 选择复旦大学附属闵行医院门诊、哮喘专病门诊和莘庄社区卫生服务中心儿科门诊于2024年1月至2025年2月收治的100例哮喘急性发作患儿为研究对象,按照随机数表法分为研究组及对照组,各50例。对照组采用醋酸泼尼松片联合特布他林及异丙托溴铵雾化治疗,研究组采用丙酸氟替卡松联合特布他林及异丙托溴铵雾化治疗,两组均持续治疗7 d。比较两组患儿治疗7 d后的临床疗效,治疗前及治疗7 d后的肺功能,肺泡气一氧化氮浓度(concentration of alveolar nitric oxide,CaNO),呼出气一氧化氮(fractional exhaled nitric oxide,Fe NO),临床症状评分,并观察患儿的临床症状消失时间及不良反应。结果 治疗7 d后,两组的临床总有效率无差异(单侧P> 0.05)。治疗前,两组患儿肺功能、Ca NO、Fe NO和临床症状评分比较均无差异(双侧P> 0.05);治疗7 d后,两组患儿的肺功能指标均提高,Ca NO、Fe NO水平均下降,但组间无差异(双侧P> 0.05),两组治疗后的日间和夜间临床症状评分均下降,但组间无差异(双侧P> 0.05)。研究组的临床症状消失时间均早于对照组(双侧P <0.05)。研究组的不良反应总发生率低于对照组(单侧P <0.05)。结论 丙酸氟替卡松联合特布他林、异丙托溴铵雾化治疗儿童哮喘急性发作的有效性高,能改善患儿的肺功能,降低Ca NO及Fe NO水平,缩短患儿的临床症状消失时间,并能减少药物不良反应。

     

    Abstract: Objective This study aimed to analyze the effect of fluticasone propionate combined with terbutaline and ipratropium bromide in the nebulized inhalation treatment of acute asthma in children. Methods 100 children with acute asthma attack admitted to the Outpatient Department and the Asthma Specialty Outpatient Department of Minhang Hospital Affiliated to Fudan University, and the Pediatric Outpatient Department of Xinzhuang Community Health Service Center from January 2024 to February 2025 were the research subjects divided into the study group and control group according to random number table method, with 50 cases in each group. The control group was treated with prednisone acetate tablets combined with terbutaline and ipratropium bromide, while the study group was treated with fluticasone propionate combined with terbutaline and ipratropium bromide, with both groups being treated for 7 days. The clinical efficacy after 7 days of treatment, pulmonary function, concentration of alveolar nitric oxide(CaNO), exhaled nitric oxide(FeNO) and clinical symptom scores between the two groups before and after 7 days of treatment, and the time for clinical symptoms to disappear and adverse reactions were observed. Results After 7 days of treatment, there was no difference in total effective rate between the two groups(one-sided P > 0.05). Before treatment, there was no differences in pulmonary function, CaNO, FeNO and clinical symptom scores between the two groups(two-sided P > 0.05); after 7 days of treatment, the lung function indexes of both groups increased, and the levels of CaNO and FeNO decreased, with no difference between the two groups(two-sided P > 0.05); the daytime and nighttime clinical symptom scores of both groups decreased after treatment, with no difference between the two groups(two-sided P > 0.05). The disappearance time of clinical symptoms in the study group was earlier than that in the control group(two-sided P < 0.05). The incidence of adverse reactions in the study group was lower than that in the control group(one-sided P < 0.05). Conclusion Fluticasone propionate combined with terbutaline and ipratropium bromide is highly effective in the treatment of acute asthma in children, which can improve lung function, reduce CaNO and FeNO levels, shorten the time for clinical symptoms to disappear, and reduce adverse drug reactions.

     

/

返回文章
返回